top of page

Detecting Cancer Recurrence Sooner [STAT Summit 2026 Review #35]

Nov 12
5 min read

Report 35. Detecting Cancer Recurrence Sooner

Part I. English Version


1. Event / Date & Time

Event: Detecting Cancer Recurrence Sooner | Sponsored by Foundation Medicine

Conference: STAT Summit 2026

Date & Time: October 15, 2026 | 3:40 PM EDT


2. Participants

Speakers

- Troy Schurr — Chief Commercial Officer, Foundation Medicine


Moderator

- Lison Joseph — Health Tech Editor, STAT


3. Summary

Molecular Residual Disease: Tumor-informed blood-based testing may detect signs of cancer recurrence earlier than conventional imaging in selected settings.


Precision Diagnostics Infrastructure: Foundation Medicine described leveraging comprehensive genomic profiling and Roche’s wider diagnostic capabilities.


Evidence and Uptake: Prospective validation, clinician education and reimbursement pathways remain important for translating molecular monitoring into care.


4. Main Discussion

From Genomic Profiling to Recurrence Monitoring

Schurr introduced Foundation Medicine’s genomic diagnostics, including tissue and liquid-biopsy approaches. He described molecular residual disease (MRD) testing that first characterizes tumor material and then looks for associated signals in blood. Such tests may reveal residual cancer or recurrence before changes become detectable on imaging, depending on the clinical situation.

Schurr positioned molecular residual disease testing within a wider diagnostic portfolio that uses solid-tumor material, blood and hematologic cancer samples. In a tumor-informed workflow, a sample of the patient’s tumor is first characterized and subsequent blood draws are analyzed for matching molecular signals. The aim is to detect traces of disease that may persist after treatment or emerge during follow-up, potentially before conventional imaging reveals recurrence. Such earlier signals can create additional decision points for physicians, but their interpretation depends on the cancer type, assay characteristics and planned intervention. The session distinguished the ability to detect a molecular marker from proof that responding to it will improve survival or another patient-important outcome.

Schurr distinguished comprehensive genomic profiling from molecular residual disease (MRD) monitoring. Profiling characterizes mutations and other biomarkers that may guide therapy selection, whereas MRD testing looks for very small amounts of tumor-derived material after treatment and may provide information before recurrence is visible on conventional imaging. In the approach he described, tissue information helps create a tumor-informed assay and subsequent blood samples are tested over time. This is a potential source of earlier warning, not the same as proving that every molecular signal represents clinically actionable disease. The value of early detection ultimately depends on whether clinicians can take steps that improve patient outcomes.


Diagnostic Scale and Roche Integration

He said the company has been operating for nearly 16 years and cited more than 100 FDA-approved companion diagnostic applications. As a Roche affiliate since 2018, Foundation Medicine aims to leverage broader sequencing, pathology and diagnostics capabilities to scale innovation. These figures were presented by the speaker.

Foundation Medicine was described as a Roche affiliate since 2018, a relationship Schurr said makes broader sequencing, pathology and diagnostics resources available to the business. He cited almost sixteen years of company operations and more than one hundred FDA-approved companion-diagnostic applications. These were company-reported figures in the session and were not independently audited there. Roche’s sequencing and pathology-related capabilities were presented as potential means of integrating tests with clinical workflows and drug development. The strategic advantage envisioned is not merely another assay but the ability to connect molecular insights to drug selection, follow-up care and partnerships with pharmaceutical developers.

Foundation Medicine was presented as a genomic diagnostics business operating across solid tumors, hematologic disease and blood-based approaches. Schurr highlighted more than 100 FDA-approved companion-diagnostic indications or claims within its portfolio, while describing the company’s integration into Roche since 2018. He suggested that shared scientific platforms, sequencing development and Roche’s acquisition of PathAI could support broader diagnostic workflows. These points show the company’s commercial and technological position but are not independent proof of superiority over competing tests. The particular performance of an MRD assay must be evaluated separately from the parent company’s scale or the historical success of other genomic products.


Evidence Needed for Clinical Actionability

Schurr emphasized that detecting molecular signals is not the same as proving that changing treatment improves outcomes. He noted opportunities for prospective studies and partnerships with biopharma companies on cohort selection, treatment optimization and monitoring. The discussion framed actionable clinical evidence as necessary for routine adoption.

Successful MRD development also requires clarity about what action follows a positive test. More sensitive detection might lead to intensified imaging, additional diagnostic workup, clinical-trial eligibility discussions or treatment decisions, but the benefits and harms of each response need evidence. Without prospective studies, earlier knowledge may simply extend the period of uncertainty or introduce avoidable procedures. Schurr described opportunities to collaborate with biopharma partners on patient selection and treatment monitoring, linking diagnostics to therapeutic development. The session suggested that the value of the test depends on demonstrating clinical usefulness within an explicit care pathway, including whether the information changes management for the better.

Clinical implementation requires consideration of sensitivity, specificity, sampling frequency, false positives and the consequences of acting on molecular findings. A test that detects a signal earlier may create anxiety, additional imaging or treatment changes without necessarily extending life if no effective intervention is available. Conversely, in settings with a proven response strategy, reliable molecular monitoring might help tailor follow-up or identify patients for clinical trials. The session did not provide a definitive randomized estimate of improved survival from the new test. It was primarily a company presentation about an emerging diagnostic service and its potential applications across the care continuum.


Clinician Awareness and Implementation

Schurr estimated that broader biomarker testing adoption was roughly 50–60%, highlighting substantial room for improvement. Education, workflow integration and evidence-based indications were discussed as requirements for expanding appropriate molecular testing.

Schurr estimated that only about 50–60% of eligible biomarker testing was being adopted in relevant practice settings, indicating a gap between available diagnostics and routine use. The session identified clinician awareness, logistics, coverage and the integration of testing into existing oncology visits as practical challenges. These observations applied to biomarker testing more generally and should not be misread as a validated utilization estimate for the newly discussed MRD product alone. Broad implementation will require patient and clinician education, ordering and result-return processes, payer evidence and follow-up resources. The industrial challenge is to combine sophisticated analytics with a workable clinical service rather than expecting accuracy alone to drive uptake.

Schurr also described the need to raise clinician awareness of when and how a new monitoring test should be ordered. A molecular result is only one step in a care pathway: the ordering oncologist must understand the limitations, communicate uncertainty to the patient, and plan follow-up in light of available therapies and imaging results. Payers and healthcare systems will need evidence of appropriate testing frequency and whether an altered treatment course improves meaningful outcomes. Pharmaceutical partners may also use monitoring data to support clinical development, but those exploratory uses are distinct from a validated routine-care indication. This reinforces the separation between analytical performance, clinical validity and demonstrated clinical utility.


5. Insights

Actionable Molecular Monitoring: MRD innovation should be assessed by whether earlier detection leads to better treatment decisions and outcomes, not detection alone.


Implications for South Korea: Korea could explore prospective studies linking molecular recurrence testing with clinical interventions and reimbursement evidence.


Diagnostics–Therapeutics Collaboration: Partnerships among diagnostic laboratories, oncology centers and drug developers may strengthen precision follow-up care.



Comments


© 2026 KHIDI USA ALL RIGHT RESERVED

bottom of page